A5036997635- CAR-T cell therapy research
- Drug Transport and Resistance Mechanisms
- Eosinophilic Disorders and Syndromes
- Virus-based gene therapy research
- Acute Myeloid Leukemia Research
- Nanowire Synthesis and Applications
- Pneumocystis jirovecii pneumonia detection and treatment
- Engineering Applied Research
- Viral-associated cancers and disorders
- Bone and Joint Diseases
- Platelet Disorders and Treatments
- Hematopoietic Stem Cell Transplantation
- Advanced Sensor and Control Systems
- Liver Disease Diagnosis and Treatment
- Nanoparticle-Based Drug Delivery
- IgG4-Related and Inflammatory Diseases
- Pituitary Gland Disorders and Treatments
- Hematological disorders and diagnostics
- Immune Cell Function and Interaction
- Advanced Computing and Algorithms
- Chronic Lymphocytic Leukemia Research
- Interstitial Lung Diseases and Idiopathic Pulmonary Fibrosis
- Growth Hormone and Insulin-like Growth Factors
- Advanced Optical Sensing Technologies
- Chronic Myeloid Leukemia Treatments
Nagoya University
2020-2023
Sumitomo Dainippon Pharma (Japan)
2011-2021
Konan Kosei Hospital
2013-2015
Hosei University
2008
Denso (United States)
2002
Adoptively transferred CD19 chimeric antigen receptor (CAR) T cells have led to impressive clinical outcomes in B cell malignancies. Beyond induction of remission, the persistence CAR-T is required prevent relapse and provide long-term disease control. To improve function persistence, we developed a composite co-stimulatory domain signaling moiety, CD79A/CD40, induce nuclear translocating signal, NF-κB, synergize with other signals function. CD79A/CD40 incorporating CD19CAR-T (CD19.79a.40z)...
TAFRO syndrome have been proposed as a rare variant of Castleman's disease. This article reports case 56-year-old man with who was successfully treated thalidomide in spite the refractoriness to prednisolone and tocilizumab. Thalidomide may be one treatment options for syndrome.
Metabolomics follows the changes in concentrations of endogenous metabolites, which may reflect various disease states as well systemic responses to environmental, therapeutic, or genetic interventions. In this study, we applied metabolomic approaches monitor dynamic plasma and urine compared these metabolite profiles Eisai hyperbilirubinemic rats (EHBR, an animal model cholestasis) with those parent strain EHBR - Sprague-Dawley (SD) order characterize cholestasis pathophysiologically....
An artificial T cell adaptor molecule (ATAM) was generated to improve persistence of receptor (TCR) gene-transduced (TCR-T) cells compared such in a preceding study. ATAMs are gene-modified CD3ζ with the intracellular domain 4-1BB inserted middle CD3ζ. NY-ESO-1 TCR-T transduced an ATAM two separated virus vectors demonstrated superior proliferation upon antigen stimulation. To further develop clinically applicable ATAM-transduced cells, we attempted make single vector transduce TCR and...
Abstract Chimeric antigen receptor T (CAR-T) cells targeting multiple antigens (Ag), may reduce the risk of immune escape following loss target Ag and further increase efficacy treatment. We developed dual-targeting CAR-T that CD19 CD37 Ags evaluated their antitumor effects. CD19/CD37 dual were generated using cotransduction simultaneous gene transfer two types lentiviral vectors transferring CD19CAR or CD37CAR genes, including intracellular domains CD28 CD3ζ signaling domains. These...
We herein present the case of a 30-year-old man who developed recurrent pancreatitis and chronic graft-versus-host disease following unrelated bone marrow transplantation for acute myeloid leukemia (AML) with t(16;21)(p11;q22). Autoimmune was initially suspected due to radiological findings lack response gabexate mesilate antibiotics. An examination specimens successfully obtained via endoscopic ultrasound-guided fine needle aspiration (EUS-FNA) demonstrated invasion AML cells in pancreatic...
A piezoresistance type 3-D acceleration sensor is used for analysis of walking under various measurement conditions. The set to the center person's waist. differences due conditions in information were extracted and estimation stride length from amplitude was proposed.
<p>Supplemental Figure S2. Evaluation of cytokine production against tumor cells isolated from patients who relapsed after CAR-T cell therapy. A, Expression CD19, CD20, and CD37 in diffuse large B-cell lymphoma a patient treatment with tisagenlecleucel. B, Intracellular IL-2 or IFN-γ positive stimulation the at an E:T ratio 1:1 for 4 h.</p>
<p>Supplemental Figure S1. CD19 and CD37 expression of EBV-LCL. EBV-LCL was stained with CD19-PE CD37-FITC mAb, respectively. Grey tinted area indicated isotype control staining.</p>
<p>Supplemental Figure S1. CD19 and CD37 expression of EBV-LCL. EBV-LCL was stained with CD19-PE CD37-FITC mAb, respectively. Grey tinted area indicated isotype control staining.</p>
<div>Abstract<p>Chimeric antigen receptor T (CAR-T) cells targeting multiple antigens (Ag), may reduce the risk of immune escape following loss target Ag and further increase efficacy treatment. We developed dual-targeting CAR-T that CD19 CD37 Ags evaluated their antitumor effects. CD19/CD37 dual were generated using cotransduction simultaneous gene transfer two types lentiviral vectors transferring CD19CAR or CD37CAR genes, including intracellular domains CD28 CD3ζ signaling...
<div>Abstract<p>Chimeric antigen receptor T (CAR-T) cells targeting multiple antigens (Ag), may reduce the risk of immune escape following loss target Ag and further increase efficacy treatment. We developed dual-targeting CAR-T that CD19 CD37 Ags evaluated their antitumor effects. CD19/CD37 dual were generated using cotransduction simultaneous gene transfer two types lentiviral vectors transferring CD19CAR or CD37CAR genes, including intracellular domains CD28 CD3ζ signaling...
<p>Supplemental Figure S3. Analysis of differentiation markers CAR-T cells. Each cells and tEGFR-T were stimulated with CD19/CD37 positive Raji at a 1:5 ratio every 7 days stained for CD62L, CD45RA, CCR7, CD27 CD28. A, B, Summary data the percentage CD45RA-/CD62L+ central memory T (TCM) cell fraction (A) CD45RA-/CD62L- effecter (TEM) (B). C–E, CCR7-/CD27+/CD28+ early TEM (C), CCR7-/CD27+/CD28- late (D) CCR7-/CD27-/CD28- (E). Data represent mean ± SEM from five different donors (two-way...
<p>Supplemental Figure S3. Analysis of differentiation markers CAR-T cells. Each cells and tEGFR-T were stimulated with CD19/CD37 positive Raji at a 1:5 ratio every 7 days stained for CD62L, CD45RA, CCR7, CD27 CD28. A, B, Summary data the percentage CD45RA-/CD62L+ central memory T (TCM) cell fraction (A) CD45RA-/CD62L- effecter (TEM) (B). C–E, CCR7-/CD27+/CD28+ early TEM (C), CCR7-/CD27+/CD28- late (D) CCR7-/CD27-/CD28- (E). Data represent mean ± SEM from five different donors (two-way...
<p>Supplemental Figure S2. Evaluation of cytokine production against tumor cells isolated from patients who relapsed after CAR-T cell therapy. A, Expression CD19, CD20, and CD37 in diffuse large B-cell lymphoma a patient treatment with tisagenlecleucel. B, Intracellular IL-2 or IFN-γ positive stimulation the at an E:T ratio 1:1 for 4 h.</p>